keyword
MENU ▼
Read by QxMD icon Read
search

Pegfilgrastim

keyword
https://www.readbyqxmd.com/read/27928760/cost-effectiveness-analysis-of-prophylaxis-treatment-strategies-to-reduce-the-incidence-of-febrile-neutropenia-in-patients-with-early-stage-breast-cancer-or-non-hodgkin-lymphoma
#1
Kelly Fust, Xiaoyan Li, Michael Maschio, Guillermo Villa, Anju Parthan, Richard Barron, Milton C Weinstein, Luc Somers, Caroline Hoefkens, Gary H Lyman
OBJECTIVE: The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the incidence of febrile neutropenia (FN) in patients with stage II breast cancer receiving TC (docetaxel, cyclophosphamide) and in patients with non-Hodgkin lymphoma (NHL) receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) over a lifetime horizon from a Belgian payer perspective...
December 7, 2016: PharmacoEconomics
https://www.readbyqxmd.com/read/27904448/mobilization-with-cyclophosphamide-reduces-the-number-of-lymphocyte-subpopulations-in-the-leukapheresis-product-and-delays-their-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-in-patients-with-multiple-myeloma
#2
Matevz Skerget, Barbara Skopec, Darja Zontar, Peter Cernelc
BACKGROUND: Autologous hematopoietic stem cell transplantation is considered the standard of care for younger patients with multiple myeloma. Several mobilization regimens are currently used, most commonly growth factors alone or in combination with chemotherapy. The aim of our study was to investigate the differences in lymphocyte subpopulation counts between three different mobilization regimens on collection day, in the leukapheresis product and on day 15 after autologous hematopoietic stem cell transplantation...
December 1, 2016: Radiology and Oncology
https://www.readbyqxmd.com/read/27822615/g-csf-use-in-patients-receiving-first-line-chemotherapy-for-non-hodgkin-s-lymphoma-nhl-and-granulocyte-colony%C3%A2-stimulating-factors-g-csf-as-observed-in-clinical-practice-in-italy
#3
Umberto Vitolo, Francesco Angrili, Lucy DeCosta, Sally Wetten, Massimo Federico
Treatment of non-Hodgkin lymphoma (NHL) requires chemotherapy regimens with significant risk of febrile neutropenia (FN). For patients at ≥20% FN risk, guidelines recommend primary prophylaxis (PP) with granulocyte-colony stimulating factor (G-CSF). This study assessed whether G-CSF use in NHL was in line with recommendations in routine practice. This was a retrospective, observational study of adult NHL patients receiving first-line (R)CHOP-like chemotherapy and G-CSF support between June 2010 and 2012, in Italy...
December 2016: Medical Oncology
https://www.readbyqxmd.com/read/27819161/performance-of-the-pegfilgrastim-on-body-injector-as-studied-with-placebo-buffer-in-healthy-volunteers
#4
Rajeshree S Joshi, Ogo I Egbuna, Alex S Cairns, Michael J Friedman, Bassam Abosaleem, Maureen T Reiner, Phuong Khanh Morrow
OBJECTIVE: The pegfilgrastim on-body injector (OBI) is a single-use, disposable, battery-powered injector that is designed to automatically deliver a single subcutaneous dose of pegfilgrastim beginning approximately 27 hours after activation and continuing over approximately 45 minutes. In this open-label study, we assessed performance of the OBI delivering placebo buffer in healthy volunteers. RESEARCH DESIGN AND METHODS: Healthy men and women aged 18-55 years, with a body mass index of 18-35 kg/m(2), were enrolled...
December 2, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27783280/optimal-primary-febrile-neutropenia-prophylaxis-for-patients-receiving-docetaxel-cyclophosphamide-chemotherapy-for-breast-cancer-a-systematic-review
#5
REVIEW
Ricardo Fernandes, Sasha Mazzarello, Carol Stober, Lisa Vandermeer, Shaan Dudani, Mohamed F K Ibrahim, Habeeb Majeed, Kirstin Perdrizet, Risa Shorr, Brian Hutton, Dean Fergusson, Mark Clemons
BACKGROUND: Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics] is unknown. A systematic review was performed to address this knowledge gap. METHODS: Embase, Ovid Medline, Pubmed, the Cochrane database of systematic reviews, and Cochrane register of controlled trials were searched from 1946 to April 2016 for studies evaluating primary prophylactic FN treatments in breast cancer patients receiving DC chemotherapy...
October 25, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27774364/pancytopenia-and-severe-gastrointestinal-toxicities-associated-with-5-fluorouracil-in-a-patient-with-thymidylate-synthase-tyms-polymorphism
#6
Bo Wang, Shannon J Walsh, Muhammad W Saif
5-Fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in solid tumors, including colon, gastric and breast cancers. The pharmacogenetic syndrome of dihydropyrimidine dehydrogenase (DPD) deficiency leading to severe toxicity after administration of 5-flourouracil (5-FU) and capecitabine has been well-recognized. However, the data about the association of the target enzyme, thymidylate synthase (TYMS) with the toxicity of these agents is limited. A 50-year-old Caucasian woman with T2N2M0 Stage IIIB squamous cell rectal cancer after local surgical excision initiated 5-FU therapy with mitomycin-C and radiation therapy in the adjuvant setting...
September 21, 2016: Curēus
https://www.readbyqxmd.com/read/27751704/when-hydromorphone-is-not-working-try-loratadine-an-emergency-department-case-of-loratadine-as-abortive-therapy-for-severe-pegfilgrastim-induced-bone-pain
#7
Katherine Moore, Rachel Haroz
BACKGROUND: Intractable bone pain is a notorious adverse effect of granulocyte-colony stimulating factors (G-CSFs), such as pegfilgrastim and filgrastim, which are given to help prevent neutropenia in patients who are undergoing chemotherapy. G-CSF-induced bone pain is surprisingly common and often refractory to treatment with conventional analgesics. CASE REPORT: This article describes an emergency department case of opiate and nonsteroidal anti-inflammatory drug-resistant pegfilgrastim-induced bone pain that was successfully alleviated with 10 mg of oral loratadine, allowing for discharge home...
October 14, 2016: Journal of Emergency Medicine
https://www.readbyqxmd.com/read/27688102/partner-an-open-label-randomized-phase-2-study-of-docetaxel-cisplatin-chemotherapy-with-or-without-panitumumab-as-first-line-treatment-for-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck
#8
Lori J Wirth, Shaker Dakhil, Gabriela Kornek, Rita Axelrod, Douglas Adkins, Shubham Pant, Paul O'Brien, Philip R Debruyne, Kelly S Oliner, Jun Dong, Swami Murugappan
OBJECTIVE: This phase 2 estimation study evaluated docetaxel/cisplatin with/without panitumumab, an anti-epidermal growth factor receptor monoclonal antibody, as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Randomized patients received docetaxel/cisplatin (75mg/m(2) each) with/without panitumumab (9mg/kg) in 21-day cycles. Patients randomized to panitumumab+chemotherapy could continue panitumumab monotherapy after completing six chemotherapy cycles without progression; patients randomized to chemotherapy alone could receive second-line panitumumab after progression...
October 2016: Oral Oncology
https://www.readbyqxmd.com/read/27649817/feasibility-and-kinetics-of-cd34-hematopoietic-progenitor-cell-mobilization-in-response-to-a-single-administration-of-docetaxel-chemotherapy-and-pegfilgrastim-in-a-contemporary-cohort-of-patients-with-metastatic-breast-cancer
#9
Harminder Takhar, Anna Rachelle Mislang, Nimit Singhal, Michael P Brown
AIM: Autologous hematopoietic stem cell transplantation (auto-HSCT) remains an experimental therapy for metastatic breast cancer (MBC) and there is no established protocol for cluster of differentiation 34(+) (CD34(+) ) hematopoietic progenitor cell (HPC) mobilization with historic studies using growth factors with or without chemotherapy. This study describes the feasibility and kinetics of CD34(+) HPC mobilization following a single administration of docetaxel and the pegylated form of recombinant human granulocyte colony-stimulating factor analogue filgrastim (pegfilgrastim)...
September 21, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27647222/safety-and-efficacy-of-dose-dense-chemotherapy-with-tcf-regimen-in-elderly-patients-with-locally-advanced-or-metastatic-gastric-cancer
#10
Wanda Liguigli, Gianluca Tomasello, Laura Toppo, Rossana Poli, Silvia Lazzarelli, Federica Negri, Bruno Perrucci, Alessandra Curti, Matteo Brighenti, Gianvito Donati, Morena Nazzari, Mario Martinotti, Marco Vismarra, Massimo Rovatti, Rodolfo Passalacqua
PURPOSE: To evaluate the efficacy and safety of dose-dense TCF in elderly (≥65 years) compared to younger patients. METHODS: Safety and efficacy data relative to 119 consecutive patients with locally advanced or metastatic gastric cancer treated at our institution and enrolled in different phase II trials were retrospectively collected. All patients were treatment-naive and received docetaxel 70 mg/m2 day 1, cisplatin 60 mg/m2 day 1, l-folinic acid 100 mg/m2 days 1-2, followed by 5-fluorouracil 400 mg/m2 bolus days 1-2, and then 600 mg/m2 as a 22-hour continuous infusion days 1-2, every 14 days, plus pegfilgrastim 6 mg on day 3...
August 23, 2016: Tumori
https://www.readbyqxmd.com/read/27628549/-the-clinical-utility-of-pegfilgrastim-in-combination-with-adjuvant-fec-100-and-tc-chemotherapy-for-breast-cancer
#11
Hirotsugu Yanai, Kayoko Endo, Mayumi Matsumoto, Masanori Kon, Tomoharu Sugie
BACKGROUND: More than 20%of breast cancer patients who undergo myelosuppressive chemotherapy involving FEC(100) or TC experience febrile neutropenia(FN), and pegfilgrastim is commonly recommended as the primary prophylaxis. Delays and/or dose-reductions in chemotherapy should be avoided as much as possible to maximize the clinical benefits of these adjuvant chemotherapies. PURPOSE: This study assessed the relative dose intensity(RDI), efficacy, and safety of pegfilgrastim in patients with breast cancer...
September 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27621310/long-term-use-of-pegfilgrastim-in-children-with-severe-congenital-neutropenia-clinical-and-pharmacokinetic-data
#12
Francesca Fioredda, Tiziana Lanza, Federica Gallicola, Francesca Riccardi, Marina Lanciotti, Elena Mastrodicasa, Sara Signa, Sabrina Zanardi, Michaela Calvillo, Carlo Dufour
No abstract text is available yet for this article.
September 12, 2016: Blood
https://www.readbyqxmd.com/read/27572552/cost-effectiveness-of-febrile-neutropenia-prevention-with-primary-versus-secondary-g-csf-prophylaxis-for-adjuvant-chemotherapy-in-breast-cancer-a-systematic-review
#13
REVIEW
T Younis, D Rayson, S Jovanovic, C Skedgel
The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant chemotherapy (AC) regimens in breast cancer (BC) could be affected by its "value for money". This systematic review examined (i) cost-effectiveness of PP versus SP, (ii) FN threshold at which PP is cost-effective including the guidelines 20 % threshold and (iii) potential impact of G-CSF efficacy assumptions on outcomes. The systematic review identified all cost-effectiveness/cost-utility analyses (CEA/CUA) involving PP versus SP G-CSF for AC in BC that met predefined inclusion/exclusion criteria...
October 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27544379/granulocyte-colony-stimulating-factor-ameliorates-skeletal-muscle-dysfunction-in-amyotrophic-lateral-sclerosis-mice-and-improves-proliferation-of-sod1-g93a-myoblasts-in-vitro
#14
Amaya Rando, Samanta Gasco, Miriam de la Torre, Alberto García-Redondo, Pilar Zaragoza, Janne M Toivonen, Rosario Osta
BACKGROUND: Amyotrophic lateral sclerosis (ALS) causes loss of upper and lower motor neurons as well as skeletal muscle (SKM) dysfunction and atrophy. SKM is one of the tissues involved in the development of ALS pathology, and studies in a SOD1-G93A mouse model of ALS have demonstrated alterations in SKM degeneration/regeneration marker expression in vivo and defective mutant myoblast proliferation in vitro. Granulocyte colony-stimulating factor (G-CSF) has been shown to alleviate SOD1-G93A pathology...
August 20, 2016: Neuro-degenerative Diseases
https://www.readbyqxmd.com/read/27445479/new-developments-in-the-treatment-of-chemotherapy-induced-neutropenia-focus-on-balugrastim
#15
REVIEW
Michele Ghidini, Jens Claus Hahne, Francesco Trevisani, Stefano Panni, Margherita Ratti, Laura Toppo, Gianluca Tomasello
Neutropenia and febrile neutropenia are two major complications of chemotherapy. Dose reductions, delays in treatment administration, and the use of granulocyte colony-stimulating factors are equally recommended options to preserve absolute neutrophil count in case of chemotherapy regimens bringing a risk of febrile neutropenia of 20% or higher. Recombinant granulocyte colony-stimulating factors, such as filgrastim and lenograstim, have a short elimination half-life (t1/2) and need to be used daily, while others, like pegfilgrastim and lipegfilgrastim, are characterized by a long t1/2 requiring only a single administration per cycle...
2016: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/27431641/-a-pancreatic-cancer-patient-in-whom-pegfilgrastim-prophylaxis-did-not-prevent-severe-neutropenia-caused-by-the-folfirinox-regimen
#16
Takayoshi Kiba, Yuko Saito, Chiaki Otomo, Miho Sato, Takayoshi Meguro
Recently, newer agents in regimens such as FOLFIRINOX have shown promising activity, being superior to gemcitabine as a single agent for unresectable pancreatic cancer patients with good performance status. Herein, we report a case of pancreatic cancer treated with the FOLFIRINOX regimen and pegfilgrastim prophylaxis as second-line treatment in a patient who failed this regimen. He previously received gemcitabine/nab-paclitaxel combination chemotherapy as first-line treatment. It was reported that grade 3-4 neutropenia frequently occurred in many patients receiving the FOLFIRINOX regimen...
July 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27419145/immunogenicity-assessment-of-lipegfilgrastim-in-patients-with-breast-cancer-receiving-chemotherapy
#17
Linglong Zou, Anton Buchner, Martin Roberge, Patrick M Liu
Lipegfilgrastim is a long-acting, once-per-cycle, glycopegylated recombinant granulocyte colony-stimulating factor (G-CSF) used to prevent neutropenia in patients receiving myelosuppressive chemotherapy. This integrated analysis examined the immunogenicity of lipegfilgrastim and its potential clinical impact in two double-blind randomized studies (phases II and III) of patients with breast cancer receiving chemotherapy. Serum samples were analyzed using sequential assays for screening, confirmation, antibody titer, and characterization of antidrug antibodies (ADA)...
2016: Journal of Immunology Research
https://www.readbyqxmd.com/read/27374464/everolimus-combined-with-r-chop-21-for-new-untreated-diffuse-large-b-cell-lymphoma-ncctg-1085-alliance-safety-and-efficacy-results-of-a-phase-1-and-feasibility-trial
#18
Patrick B Johnston, Betsy LaPlant, Ellen McPhail, Thomas M Habermann, David J Inwards, Ivana N Micallef, Joseph P Colgan, Grzegorz S Nowakowski, Stephen M Ansell, Thomas E Witzig
BACKGROUND: The PI3K-mTORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTOR complex 1 (mTORC1) inhibitor everolimus. Everolimus has activity in relapsed DLBCL. These data provide the rationale to combine everolimus with standard treatment for DLBCL of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone delivered in a 21-day cycle (R-CHOP-21) for six cycles. METHODS: We did a phase 1 and feasibility study (NCCTG 1085) of oral everolimus 10 mg/day plus R-CHOP-21 in patients aged at least 18 years with new, untreated, CD20-positive DLBCL (stages II-IV) in the NCCTG (Alliance) National Cancer Institute Cooperative Group (USA)...
July 2016: Lancet Haematology
https://www.readbyqxmd.com/read/27220788/-safety-and-tolerance-of-dose-dense-epirubicin-and-cyclophosphamide-ec-with-pegfilgrastim-for-japanese-patients-with-early-breast-cancer
#19
Kenichi Watanabe, Masako Sato, Mitsugu Yamamoto, Mayuko Ikarashi, Kanako Hagio, Nobumoto Tomioka, Shinya Tamaki, Yumi Takahashi, Masato Takahasi
With the approval of pegfilgrastim, the use of dose-dense epirubicin and cyclophosphamide (EC) for breast cancer has become acceptable in Japan. Thus, we aimed to evaluate its safety and tolerability in Japanese patients. Nine breast cancer patients with a high risk of preoperative or postoperative recurrence received EC therapy(epirubicin 90 mg/m(2) and cyclo- phosphamide 600 mg/m(2))for 4 cycles every 2 weeks in combination with a subcutaneous injection of pegfilgrastim (3.6 mg) on day 2 of each cycle. Treatment was discontinued in 1 and extended in 1 of the 9 patients, and the mean relative dose intensity(RDI)was good at 0...
April 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/27188649/long-term-follow-up-of-a-phase-ii-trial-of-six-cycles-of-dose-dense-r-chop-14-for-first-line-treatment-of-diffuse-large-b-cell-lymphoma-in-young-and-elderly-patients
#20
Eva González-Barca, Miguel A Canales, Antonio Salar, Secundino Ferrer, Eva Domingo-Domenech, María-Jesús Vidal, Carlos Grande, Joan Bargay, Santiago Gardella, Albert Oriol, Javier Briones, Javier García-Frade, Jose L Bello, Jose J Sánchez-Blanco, Francisco Javier Peñalver, Jose Francisco Tomás, Antonio Asensio, Andrés López, Dolores Caballero
BACKGROUND/AIMS: Rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 14 days seems to achieve better outcomes than R-CHOP every 21 days in diffuse large B-cell lymphoma (DLBCL) patients. Currently, the standard regimen is R-CHOP every 21 days. METHODS: This is a phase II clinical trial of treatment with 6 cycles of R-CHOP-14 with pegfilgrastim support in 2 populations of previously untreated DLBCL patients aged ≥65 years (n = 73) or <65 years (n = 51) with low-risk International Prognostic Index scores (0-2)...
2016: Acta Haematologica
keyword
keyword
37851
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"